{
    "ticker": "ACP.PRA",
    "name": "Acer Therapeutics Inc.",
    "description": "Acer Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases. Established in 2013, Acer aims to address the unmet medical needs of patients with serious and life-threatening conditions. The company is dedicated to advancing its proprietary products, including therapies for urea cycle disorders and other metabolic diseases. Acer's lead product candidate, ACER-001, is currently in clinical development for the treatment of hyperammonemia in patients with urea cycle disorders. The company emphasizes a patient-centric approach, collaborating with healthcare professionals and patient advocacy groups to ensure that its therapies meet the needs of those affected by rare diseases. With a robust pipeline and a commitment to scientific excellence, Acer is poised to make a significant impact in the field of rare disease therapeutics. The company's mission is to provide hope and improved outcomes for patients through innovative treatments, while navigating the complex regulatory landscape of drug development.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2013",
    "website": "https://www.acertx.com",
    "ceo": "Chris Schelling",
    "social_media": {
        "twitter": "https://twitter.com/AcerTherapeutics",
        "linkedin": "https://www.linkedin.com/company/acer-therapeutics/"
    },
    "investor_relations": "https://www.acertx.com/investors",
    "key_executives": [
        {
            "name": "Chris Schelling",
            "position": "CEO"
        },
        {
            "name": "Richard L. Krawczyk",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Rare Disease Therapies",
            "products": [
                "ACER-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Acer Therapeutics Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Explore Acer Therapeutics Inc., a biopharmaceutical company dedicated to developing treatments for rare diseases. Learn about their innovative therapies and commitment to patient care.",
        "keywords": [
            "Acer Therapeutics",
            "Biopharmaceuticals",
            "Rare Diseases",
            "ACER-001",
            "Healthcare Innovation"
        ]
    },
    "faq": [
        {
            "question": "What is Acer Therapeutics known for?",
            "answer": "Acer Therapeutics is known for developing and commercializing innovative therapies for rare diseases."
        },
        {
            "question": "Who is the CEO of Acer Therapeutics?",
            "answer": "Chris Schelling is the CEO of Acer Therapeutics Inc."
        },
        {
            "question": "Where is Acer Therapeutics headquartered?",
            "answer": "Acer Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Acer Therapeutics' lead product candidate?",
            "answer": "Acer Therapeutics' lead product candidate is ACER-001, aimed at treating hyperammonemia in patients with urea cycle disorders."
        },
        {
            "question": "When was Acer Therapeutics founded?",
            "answer": "Acer Therapeutics was founded in 2013."
        }
    ],
    "competitors": [
        "VRTX",
        "NVS",
        "SNY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "ABBV",
        "BMY"
    ]
}